New CBD delivery format showing up available alternatives

Published 23-NOV-2022 12:00 P.M.

2 min read

Yesterday, our innovative cannabis Investment Bod Australia (ASX:BOD) announced positive results from a Phase 1 Clinical Trial of its novel cannabidiol (CBD i.e. a non-hallucinogenic component of marijuana) delivery format.

The trial evaluated Bod’s ECS BioAbsorb Softgel Capsule against other delivery formats currently available, namely Epidyolex (the only FDA-approved CBD drug currently) and CBD Oil across safety, tolerability and pharmacokinetic (PK) profile.

The results matter as this new delivery format is being utilised in Bod’s clinical trial for a Schedule 3 (i.e. available at your local pharmacy, no prescription required) CBD product to treat insomnia. The study supports the potential for Bod’s unique ECS BioAbsorb Soft Gel to be the benchmark delivery format for this over the counter CBD market, with the trial reporting:

Bod ECS BioAbsorb Softgel offering over 20% greater bioavailability (ie the extent a drug becomes completely available to its intended biological destination) than Epidyolex and over 400% greater than the CBD Oil solution
The maximum concentration of CBD after single oral administration of Bod ECS BioAbsorb Softgel was over 60% greater than Epidyolex and over 600% greater than CBD Oil solution.
In addition, Bod ECS BioAbsorb Softgel was twice as fast to reach maximum concentration of CBD after single oral administration of Epidyolex, and five times faster than CBD Oil solution

What’s next?

With ethics approval already granted for the clinical trial for the CBD-based insomnia treatment, we’re keen to see progress with recruitment of patients (which has already begun). Subject to the outcomes of the trial, it’s feasible that Bod could have its CBD treatment for insomnia available in pharmacies by late 2023/ 1H24.

Aside from the insomnia trial, we’re also looking forward to updates on Bod’s long Covid treatment trial as well as progress with its recent Aqua Phase technology acquisition - covered in our latest commentary BOD’s big bet – will it pay off?.